{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:04:14Z","timestamp":1790078654978,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.coviro.2013.04.007","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T07:33:28Z","timestamp":1371281608000},"page":"343-351","source":"Crossref","is-referenced-by-count":54,"title":["Vaccines for viral hemorrhagic fevers\u2014progress and shortcomings"],"prefix":"10.1016","volume":"3","author":[{"given":"Darryl","family":"Falzarano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2013.04.007_sbref0005","first-page":"e1002924","article-title":"A novel rhabdovirus associated with acute hemorrhagic fever in central Africa","volume":"8","author":"Grard","year":"2012","journal-title":"Pediatr Panam"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0010","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2013.04.007_bib0015","first-page":"e1000455","article-title":"Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa","volume":"5","author":"Briese","year":"2009","journal-title":"Pediatr Panam"},{"key":"10.1016\/j.coviro.2013.04.007_bib0020","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1371\/journal.pntd.0000388","article-title":"Risk maps of Lassa fever in West Africa","volume":"3","author":"Fichet-Calvet","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0025","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2013.04.007_bib0030","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2013.04.007_bib0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1743-422X-7-279","article-title":"Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever","volume":"7","author":"Branco","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2013.04.007_bib0040","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-10-52","article-title":"An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Running title: Lassa vaccine in SIV-positive macaques","volume":"10","author":"Zapata","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0050","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0055","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7560.1000160","article-title":"Vaccine platforms to control arenaviral hemorrhagic fevers","volume":"3","author":"Carrion","year":"2012","journal-title":"J Vaccines Vaccin"},{"key":"10.1016\/j.coviro.2013.04.007_bib0060","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/hv.7.6.15198","article-title":"Argentine hemorrhagic fever vaccines","volume":"7","author":"Ambrosio","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0065","doi-asserted-by":"crossref","first-page":"10404","DOI":"10.1128\/JVI.00856-11","article-title":"The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain","volume":"85","author":"Albarino","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0070","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2010.04.077","article-title":"TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs","volume":"28","author":"Seregin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1472-6750-12-80","article-title":"Antigen vehiculization particles based on the Z protein of Junin virus","volume":"12","author":"Borio","year":"2012","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/vbz.2010.0040","article-title":"Interventions against West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus: where are we?","volume":"10","author":"Kortekaas","year":"2010","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1473-3099(06)70435-2","article-title":"Crimean-Congo haemorrhagic fever","volume":"6","author":"Ergonul","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0090","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","article-title":"Healthy individuals\u2019 immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine","volume":"30","author":"Mousavi-Jazi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0095","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/CVI.05352-11","article-title":"Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus","volume":"18","author":"Ghiasi","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3201\/eid1608.090470","article-title":"Hantavirus infections in humans and animals, China","volume":"16","author":"Zhang","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3201\/eid1408.080221","article-title":"Puumala hantavirus excretion kinetics in bank voles (Myodes glareolus)","volume":"14","author":"Hardestam","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0115","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0264-410X(99)00057-2","article-title":"Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax)","volume":"17","author":"Cho","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14760584.8.1.67","article-title":"Recent approaches in hantavirus vaccine development","volume":"8","author":"Maes","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2013.04.007_bib0125","first-page":"766","article-title":"Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells","volume":"118","author":"Dong","year":"2005","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.coviro.2013.04.007_bib0130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000067925","article-title":"Review of an inactivated vaccine against hantaviruses","volume":"45","author":"Cho","year":"2002","journal-title":"Intervirology"},{"key":"10.1016\/j.coviro.2013.04.007_bib0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/erv.12.15","article-title":"Vaccines for hantaviruses: progress and issues","volume":"11","author":"Schmaljohn","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2013.04.007_bib0140","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.vaccine.2012.01.024","article-title":"A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome","volume":"30","author":"Boudreau","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"Bird","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0150","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","article-title":"Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0155","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fcimb.2012.00131","article-title":"Novel approaches to develop Rift Valley fever vaccines","volume":"2","author":"Indran","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.08.002","article-title":"Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines","volume":"84","author":"Bouloy","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0165","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins","volume":"366","author":"Gorchakov","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2013.04.007_bib0175","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.coviro.2013.04.007_bib0180","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1371\/journal.pntd.0000725","article-title":"Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus","volume":"4","author":"Bhardwaj","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0185","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1112149108","article-title":"Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice","volume":"108","author":"Papin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2013.04.007_bib0190","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2012.03.027","article-title":"Efficacy of three candidate Rift Valley fever vaccines in sheep","volume":"30","author":"Kortekaas","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0195","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0200","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/CVI.00220-10","article-title":"Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine","volume":"17","author":"Soi","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2013.04.007_bib0210","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1089\/vbz.2009.0248","article-title":"Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus","volume":"10","author":"Pichlmair","year":"2010","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0215","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"de Boer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0220","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2013.04.007_bib0225","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fvl.11.79","article-title":"Clinical aspects of Marburg hemorrhagic fever","volume":"6","author":"Mehedi","year":"2011","journal-title":"Future Virol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0230","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2013.04.007_bib0235","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2013.04.007_bib0240","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1128\/JVI.00105-07","article-title":"Successful topical respiratory tract immunization of primates against Ebola virus","volume":"81","author":"Bukreyev","year":"2007","journal-title":"J Virol"},{"issue":"Suppl. 3","key":"10.1016\/j.coviro.2013.04.007_bib0245","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2013.04.007_bib0255","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.7.4.417","article-title":"Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses","volume":"7","author":"Swenson","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2013.04.007_bib0260","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1128\/CVI.00467-09","article-title":"Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector","volume":"17","author":"Pratt","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2013.04.007_bib0265","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0270","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2013.04.007_bib0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0280","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02864-12","article-title":"Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0285","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0290","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0295","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"1893","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2013.04.007_bib0300","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0305","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1016\/j.vaccine.2011.07.017","article-title":"Next generation dengue vaccines: a review of candidates in preclinical development","volume":"29","author":"Schmitz","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl. 18","key":"10.1016\/j.coviro.2013.04.007_bib0310","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1590\/S0036-46652012000700007","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine","volume":"54","author":"Lang","year":"2012","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0315","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2013.04.007_bib0320","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.antiviral.2012.10.005","article-title":"Kyasanur forest disease","volume":"96","author":"Holbrook","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.04.007_bib0325","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(10)61120-8","article-title":"Omsk haemorrhagic fever","volume":"376","author":"Ruzek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0330","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jir122","article-title":"A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans","volume":"203","author":"Orlinger","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0335","doi-asserted-by":"crossref","first-page":"A45","DOI":"10.1016\/j.antiviral.2011.03.073","article-title":"Inactivated vaccine against tick-borne encephalitis virus as surrogate vaccine against Omsk hemorrhagic fever virus","volume":"90","author":"Terekhina","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.04.007_bib0340","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1016\/j.vaccine.2010.04.047","article-title":"Comparison of immunogenicity and safety between two paediatric TBE vaccines","volume":"28","author":"Pollabauer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0345","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","article-title":"The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever","volume":"11","author":"Jentes","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2013.04.007_bib0350","series-title":"Yellow Fever","author":"WHO","year":"2011"},{"key":"10.1016\/j.coviro.2013.04.007_bib0355","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0360","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2013.04.007_bib0365","doi-asserted-by":"crossref","first-page":"e24505","DOI":"10.1371\/journal.pone.0024505","article-title":"Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever","volume":"6","author":"Schafer","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2013.04.007_sbref0370","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2013.04.007_bib0375","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571300062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187962571300062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T07:28:00Z","timestamp":1539588480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187962571300062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S187962571300062X"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2013.04.007","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}